Homepage of the 8^th Fabisch-Symposium
for Cancer Research and Molecular Cell Biology revolving around
3rd TARGETED TUMOR THERAPIES

The symposium deals with the development of protein-based targeted tumor therapies and their clinical application, with special focus on target recognition, drug design and production, human effector proteins, and innovative strategies for improvement.

Online registration now available. Click here.

Main Topics:

• Generation and design of targeted toxins
  including antibody design, toxin selection, coupling strategies, protein production, and others
• Targeted human proteins as effectors
  including human RNases, kinases, proteases, proteins involved in apoptosis, and others
• Innovative tools to improve targeted tumor therapies
  including mutations, molecular adaptors, cleavable bonds, prodrug activation, controlled release, and others
• Targeted tumor therapies in clinical applications
  including all phases of clinical trials

Confirmed Speakers (alphabetically):

• Yvonne Andersson (Oslo, Norway)
• Michaela Arndt (Heidelberg, Germany)
• Diana Bachran (Berlin, Germany)
• Stefan Barth (Aachen, Germany)
• Thomas Bugge (Bethesda, Maryland, USA)
• Claudia De Lorenzo (Naples, Italy)
• P. Markus Deckert (Berlin / Brandenburg, Germany)
• Stefan Dübel (Braunschweig, Germany)
• Georg H. Fey (Erlangen, Germany)
• David J. Fitzgerald (Bethesda, Maryland, USA)
• David Flavell (Southampton, UK)
• Arthur E. Frankel (Temple, Texas, USA)
• Uwe Haberkorn (Heidelberg, Germany)
• Wijnand Helfrich (Groningen, Netherlands)
• Rodolfo Ippoliti (L’Aquila, Italy)
• Roland Kontermann (Stuttgart, Germany)
• Felix Kratz (Freiburg, Germany)
• Klaus Pfizenmaier (Stuttgart, Germany)
• Michael G. Rosenblum (Houston, Texas, USA)
• Andrew Thorburn (Aurora, Colorado, USA)
• Daniel A. Vallera (Minneapolis, Minnesota, USA)
• Winfried Wels (Frankfurt/M., Germany)
• Philipp Wolf (Freiburg, Germany)
• Uwe Zangemeister-Wittke (Zurich, Switzerland)

Supported by the Fabisch-Stiftung
and